

PA-IDC

QUERY CONTROL FORM		RTIS USE ONLY	
Application No.	09/771,669	Prepared by	NB
Examiner-GAU	Page - 1615	Date	9/28/04
		No. of queries	4
			IPW(PWTY)

JACKET

a. Serial No.	f. Foreign Priority	k. Print Claim(s)	p. PTO-1449
b. Applicant(s)	g. Disclaimer	l. Print Fig.	q. PTOL-85b
c. Continuing Data	h. Microfiche Appendix	m. Searched Column	r. Abstract
d. PCT	i. Title	n. PTO-270/328	s. Sheets/Figs
e. Domestic Priority	j. Claims Allowed	o. PTO-892	t. Other <i>Index of claim</i>

SPECIFICATION

- a. Page Missing
- b. Text Continuity
- c. Holes through Data
- d. Other Missing Text
- e. Illegible Text
- f. Duplicate Text
- g. Brief Description
- h. Sequence Listing
- i. Appendix
- j. Amendments
- k. Other

MESSAGE

- (1) Final column of index of claims is blank (claims renumbered box not marked).
- (2) Continuing data is listed in specification (Amend. dated 06/09/04) but not shown on the palm/b1b sheet.
- (3) Original claims 7 and 8 both depends on original claim 24. please advise/correct claim dependency.
- (4) clean copy of claims (dated 01/07/03, coded as REM, pages 6-8 are illegible → see attached. Please provide legible/cleaner copies of claim listing.

CLAIMS

- a. Claim(s) Missing
- b. Improper Dependency
- c. Duplicate Numbers
- d. Incorrect Numbering
- e. Index Disagrees
- f. Punctuation
- g. Amendments
- h. Bracketing
- i. Missing Text
- j. Duplicate Text

*Other illegible
Claim listing*

Thompson

initials *MM*.

RESPONSE

initials

CLEAN COPY OF ALL CLAIMS

D1 1. A composition with synergistic anti-inflammatory properties for use in conditions induced by inflammatory disease-causing biomolecules released from mast cells by the activation and degranulation of said mast cells, comprising a non-bovine proteoglycan and unrefined kernel olive oil, and one or more of a D-hexosamine sulfate, a flavonoid, L-adenosylmethionine, and a histamine-1-receptor antagonist, in an appropriate excipient or vehicle for oral or topical administration.

2. The composition according to claim 1, wherein said proteoglycan is selected from the group consisting of non-bovine chondroitin sulfate, keratan sulfate, dermatan sulfate and hyaluronic acid.

3. The composition according to claim 2, wherein said chondroitin sulfate is derived from shark cartilage.

4. The composition according to claim 1, wherein said hexosamine sulfate is D-glucosamine sulfate.

5. The composition according to claim 1, wherein said flavonoid is selected from the group consisting of quercetin, myricetin, genistein and kaempferol.

6. The composition according to claim 1, wherein said olive oil contains omega fatty acids and alpha-tocopherol.

7. The composition according to claim 24, said composition being for oral use, comprising 300 mg each of non-bovine chondroitin sulfate C, quercetin and D-glucosamine sulfate, in kernel olive oil.

8. The composition according to claims 7 or 24, further comprising 100 mg of L-adenosylmethionine.

D2 9. The composition according to claim 1, wherein said inflammatory disease is arthritis and said composition is contained in an ointment or cream for topical application, comprising, in mg%, chondroitin sulfate 0.05; unrefined kernel olive oil, 1-5; and one or more of D-glucosamine sulfate, 0.05; and quercetin, 0.03.

10. The composition according to claim 9, further comprising diphenhydramine, 5mg%.

D3 11. A composition according to claim 1, said composition consisting of a mouth wash composition, comprising chondroitin sulfate, 0.4 M; unrefined kernel olive oil 0.5-1.5 mg%; and one or more of D-glucosamine sulfate, 0.4 M; and quercetin, 0.3 M, in a mouth wash vehicle.

illegible

12. A composition according to claim 1, said composition consisting of a tooth paste, comprising, in mg%, chondroitin sulfate, 0.05; and unrefined kernel olive oil, 1-5%; and one or more of D-glucosamine sulfate, 0.05; and quercetin, 0.03; in a tooth paste vehicle.

13. A composition according to claim 1, said composition consisting of a sunscreen composition, comprising, in mg%, chondroitin sulfate, 0.05, and unrefined kernel oil, 1-5%; and one or more of D-glucosamine sulfate, 0.05; quercetin, 0.03; and titanium dioxide, 1-5%; in a sun screen vehicle.

22. A method of treating a subject suffering from an inflammatory disease, wherein said inflammatory disease results from biomolecules secreted from activated and degranulated mast cells, said inflammatory disease being selected from the group consisting of osteoarthritis, cancer, fibromyalgia, atherosclerosis, inflammatory bowel disease, interstitial cystitis, irritable bowel syndrome, migraines, angina, chronic prostatitis, eczema, arthritis, multiple sclerosis, psoriasis, sun burn, and periodontal disease, comprising the step of administering to said subject an effective amount of a composition according to claim 1.

23. The composition according to claim 1, wherein said histamine-1-receptor antagonist is diphenhydramine.

24. The composition according to claim 1, wherein said inflammatory disease is arthritis and said composition is designed for oral administration, comprising non-bevine chondroitin sulfate, quercetin, D-glucosamine sulfate, and unrefined kernel olive oil.

25. The composition according to claim 9, comprising, in mg%, chondroitin sulfate, 0.05; D-glucosamine sulfate, 0.05; quercetin, 0.03; and, unrefined kernel olive oil, 1-5%.

26. The composition according to claim 1 for oral use in allergic conditions, comprising chondroitin sulfate, a flavonoid selected from the group consisting of quercetin, myricetin and kaempferol, and said kernel olive oil.

27. The composition according to claim 26, comprising 200 mg each of chondroitin sulfate and kaempferol and said kernel olive oil.

28. The composition according to claim 26, comprising chondroitin sulfate and myricetin and said kernel olive oil.

29. The composition according to claim 28, supplemented with a histamine-1-receptor antagonist.

30. The composition according to claim 29, wherein said antagonist is diphenhydramine.

31. The composition according to claim 1, wherein said inflammatory disease is cancer and wherein said composition is designed for oral use, comprising 25-50 mg of genistein and

Illegible

150-300 mg of quercetin, and said kernel olive oil.

32. The composition according to claim 1, wherein said inflammatory disease is atherosclerosis with or without myocardial ischemia, comprising 100-300 mg each of chondroitin sulfate, myricetin and S-adenosylmethionine, and said kernel olive oil, in a vehicle for oral use.

33. The composition according to claim 1, wherein said inflammatory disease is interstitial cystitis, said composition comprising 100-300 mg of chondroitin sulfate, 100-300 mg of hyaluronic acid, and 200-400 mg quercetin, and said kernel olive oil, in a vehicle for oral use.

34. The composition according to claim 1, wherein said inflammatory disease is prostatitis, said composition comprising 100-200 mg of chondroitin sulfate, 100-200 mg of hyaluronic acid and 200-400 mg of quercetin, and said kernel olive oil, in a vehicle for oral use.

35. The composition according to claim 1, wherein said inflammatory disease is multiple sclerosis, said composition comprising 100-300 mg each of chondroitin sulfate, myricetin and S-adenosylmethionine, and said kernel olive oil, in a vehicle for oral use.

illegible

Issue Classification 	Application No.	Applicant(s)
	09/771,669	THEOHARIDES, THEOHARIS C.
	Examiner Sharon L. Howard	Art Unit 1615

ORIGINAL		CROSS REFERENCE(S)	
CLASS	SUBCLASS	CLASS	SUBCLASS (ONE SUBCLASS PER BLOCK)
514	886	424	49 964
INTERNATIONAL CLASSIFICATION		514	887 901
A01N	25100		
A61K	2116		
A61K	9120		
	1		
<i>Sharon Howard 7/19/04</i>		<i>Thurman K. Page</i>	
(Assistant Examiner) (Date)		Total Claims Allowed: 32	
<i>Mary Playley 7/27/04</i>		O.G. Print Claim(s) 1	O.G. Print Fig. —
(Legal Instruments Examiner) (Date)		SUPERVISORY PATENT EXAMINER TECHNOLOGY CENTER 1600 (Date)	

<input type="checkbox"/> Claims renumbered in the same order as presented by applicant				<input type="checkbox"/> CPA				<input type="checkbox"/> T.D.				<input type="checkbox"/> R.1.47			
Final	Original	Final	Original	Final	Original	Final	Original	Final	Original	Final	Original	Final	Original	Final	Original
1		31		61		91		121		151		181		152	
2		32		62		92		122		153		182		154	
3		33		63		93		123		155		183		156	
4		34		64		94		124		157		184		158	
5		35		65		95		125		159		185		160	
6		36		66		96		126		161		186		162	
7		37		67		97		127		163		187		164	
8		38		68		98		128		165		188		166	
9		39		69		99		129		167		189		168	
10		40		70		100		130		169		190		170	
11		41		71		101		131		171		191		172	
12		42		72		102		132		173		192		174	
13		43		73		103		133		175		193		176	
14		44		74		104		134		177		194		178	
15		45		75		105		135		179		195		180	
16		46		76		106		136		181		196		182	
17		47		77		107		137		183		197		184	
18		48		78		108		138		185		198		186	
19		49		79		109		139		187		199		188	
20		50		80		110		140		189		200		190	
21		51		81		111		141		191		201		192	
22		52		82		112		142		193		202		194	
23		53		83		113		143		195		203		196	
24		54		84		114		144		197		204		198	
25		55		85		115		145		199		205		200	
26		56		86		116		146		201		206		202	
27		57		87		117		147		203		207		204	
28		58		88		118		148		205		208		206	
29		59		89		119		149		207		209		208	
30		60		90		120		150		209		210		210	